Building Competency in Diabetes Education THE ESSENTIALS

TREATMENT MODALITIES: PHARMACOLOGICAL THERAPIES | 6-125

22. Imran SA, Agarwal G, Bajaj HS, Ross S. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada: Targets for glycemic control. Can J Diabetes 2018;42(Suppl 1):S42-S46. 23. Meneilly GS, Knip A, Miller DB, Sherifali D, Tessier D, Zahedi A. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada: Diabetes in older people. Can J Diabetes 2018;42(Suppl 1):S283-S295. 24. Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, Khan N, MacCallum L, Shah BR, Simpson S. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Can J Diabetes. 2018;42(Suppl 1):S88-S103. 25. Inzucchi SE. Type 2 diabetes therapy: Choosing oral agents. In Fonseca VA, ed. Clinical Diabetes: Translating Research into Practice. Philadelphia: Saunders, 2006:322-42. 26. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008. https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf. Accessed November 30, 2018. 27. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28. 28. Neal B, Perkovic V, Mahaffey KW, et al; the CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-57. 29. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57. 30. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22. 31. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44. 32. Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated hemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018;20:889-97. 33. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide in cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double- blind, randomized placebo-controlled trial. Lancet 392:1519-29.